Pfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who received it died suddenly.
The patient, a young boy, suffered a cardiac arrest after receiving Pfizer’s one-time treatment last year, the company said in an email. The boy was part of a mid-stage study, now concluded, that enrolled children between the ages of 2 and 4, the company said.
Pfizer has paused administering the same gene therapy in a separate, final-stage study while it investigates the boy’s death, the company said. That study is looking at the gene therapy, called fordadistrogene movaparvovec, to treat Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease that primarily affects boys.
Pfizer said it’s working to “evaluate our investigational gene therapy while protecting the safety of the participants, which is our top priority.”
The final-stage trial enrolled boys between the ages of 4 and 8, testing whether the therapy could slow disease progression compared to a placebo. Results from that study are expected this year.
A competing gene therapy from Sarepta Therapeutics Inc. won accelerated US approval last year.
The news was reported earlier by Stat, based on a letter posted on the website of the group Parent Project Muscular Dystrophy.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
